

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.
NCT number를 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2022.10.31. ~ 2022.11.06.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 78건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05568095	A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body	Drug: Zimberelimab Drug: Domvanalimab Drug: Nivolumab Drug: Oxaliplatin Drug: Leucovorin Drug: Fluorouracil Drug: Capecitabine	Arcus Biosciences, Inc. Gilead Sciences	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05568095
NCT04563520	SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis	Drug: aPCC-emicizumab Drug: FEIBA Drug: rFVIIa	Emory University Takeda Pharmaceuticals North America, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT04563520
NCT05567796	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo cagrilintide Drug: Placebo semaglutide	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05567796
NCT05559359	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis	Drug: Lebrikizumab Drug: Placebo Drug: Topical corticosteroid	Eli Lilly and Company Dermira, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05559359
NCT05583227	Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis	Biological: Tezepelumab Other: Placebo	AstraZeneca Amgen	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05583227
NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Drug: Alectinib Drug: Entrectinib Drug: Pralsetinib Drug: Durvalumab	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05170204
NCT05598723	BOTOX® vs. XEOMIN® for Chronic Migraine	Drug: IncobotulinumtoxinA (XEOMIN®) Drug: OnabotulinumtoxinA (BOTOX®)	Naval Medical Center Camp Lejeune	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05598723
NCT05552157	A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Drug: Gantenerumab Drug: Matching Placebo (Gantenerumab)	Washington University School of Medicine Hoffmann-La Roche Alzheimer's Association National Institute	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05552157
NCT05589818	Pembrolizumab for Advanced NSCLC and PS 2-3	Drug: Pembrolizumab	Icahn School of Medicine at Mount Sinai	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05589818
NCT05581589	Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer	Procedure: Lymphadenectomy Procedure: Radical Cystectomy Biological: Sacituzumab Govitecan	University of Washington Gilead Sciences	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05581589
NCT05575037	Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease	Drug: Dupilumab Drug: Placebo	Brigham and Women's Hospital National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05575037
NCT05540665	Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)	Drug: Daxdilimab Drug: Placebo (Normal Saline)	Horizon Therapeutics Ireland DAC Horizon Pharma Ireland, Ltd., Dublin Ireland	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05540665
NCT05534646	Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer	Drug: Apalutamide Drug: Carotuximab	Edwin Posadas, MD Enviro Therapeutics, Inc. Cedars-Sinai Medical Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05534646
NCT05519579	Intrathecal Chemoprophylaxis to Prevent Neurotoxicity Associated With Blinatumomab Therapy for Acute Lymphoblastic Leukemia	Drug: Methotrexate Drug: Blinatumomab	Northside Hospital, Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05519579
NCT05507541	TTI-622 and TTI-621 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Procedure: Biospecimen Collection Procedure: Computed Tomography Drug: Ontoprecept Biological: Pembrolizumab Procedure: Positron Emission Tomography Drug: SIRPa-	Mayo Clinic National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05507541

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

NCT05501756	Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation	Drug: Alemtuzumab	Children's Hospital Medical Center, Cincinnati	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05501756&rank=1
NCT05345002	All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma	Drug: Retifanlimab Drug: All-trans retinoic acid	Stephen Bagley, MD, MSCE Incyte Corporation University of Pennsylvania	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05345002&rank=1
NCT05260957	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).	Drug: Mosunetuzumab Drug: Polatuzumab Biological: CAR-T Cell Therapy	Lazaros Lekakis Genentech, Inc. University of Miami	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05260957&rank=1
NCT05067257	Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer	Drug: Resiniferatoxin Drug: Placebo	Sorrento Therapeutics, Inc.	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05067257&rank=1
NCT04953104	Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13	Other: Diagnostic Laboratory Biomarker Analysis Biological: Nivolumab	M.D. Anderson Cancer Center	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT04953104&rank=1
NCT04933539	Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple	Drug: Dexamethasone Drug: Carfilzomib Biological: Daratumumab	National Cancer Institute (NCI) Janssen Scientific Affairs, LLC National Institutes of Health Clinical	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT04933539&rank=1
NCT04105270	RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II	Drug: Oral Restorative Microbiota Therapy (RMT) Capsules Drug: Durvalumab 1500 mg IV Drug: Cisplatin/pemetrexed or	Masonic Cancer Center, University of Minnesota	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT04105270&rank=1
NCT05546476	Study of the Efficacy and Safety of Pongsegromab in Patients With Cancer, Cachexia and Elevated GDF-15	Drug: pongsegromab Drug: Placebo for pongsegromab	Pfizer	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05546476&rank=1
NCT05480384	Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2- Positive Cancers of the Esophagus and Gastroesophageal Junctions	Drug: Nivolumab Drug: Trastuzumab deruxtecan	Brown University AstraZeneca	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05480384&rank=1
NCT05479045	A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients	Biological: NY-ESO-1 Peptide vaccine Drug: Nivolumab	Georgetown University United States Department of Defense	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05479045&rank=1
NCT05379972	Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers	Drug: Pembrolizumab Drug: Olaparib Radiation: Stereotactic Body Radiation Therapy	University of Colorado, Denver Merck Sharp & Dohme LLC	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05379972&rank=1
NCT05376319	PR3-AAV Resilient Remission or PRRR	Drug: Obinutuzumab Drug: Rituximab	Mayo Clinic	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05376319&rank=1
NCT04865887	Pembrolizumab and Lenvatinib in Advanced Cervical Cancer	Drug: Pembrolizumab Drug: Lenvatinib	Georgetown University Merck Sharp & Dohme LLC	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT04865887&rank=1
NCT05209308	Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL	Drug: Zandelisib Drug: Rituximab Drug: Venetoclax	MEI Pharma, Inc. Kyowa Kirin, Inc.	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05209308&rank=1
NCT05060003	Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive	Drug: Atezolizumab Drug: Tiragolumab Device: Signatera Assay	Washington University School of Medicine Genentech, Inc.	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05060003&rank=1
NCT05419011	Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome	Procedure: Biopsy Procedure: Colonoscopy Drug: Nogapendekin Alfa Drug: Placebo Administration Other: Questionnaire Administration Biological: Vaccine	National Cancer Institute (NCI)	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05419011&rank=1
NCT05287113	Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS≥1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Retifanlimab Drug: INCAGN02385 Drug: INCAGN02390 Drug: Placebo	Incyte Biosciences International Incyte Corporation	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05287113&rank=1
NCT05529316	A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Drug: Botensilimab	Agenus Inc.	Phase 2	http://clinicaltrials.gov/ct2/show/study?term=NCT05529316&rank=1

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

NCT04756401	Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma	Drug: Carfilzomib Biological: Daratumumab Drug: Dexamethasone Other: Quality-of-Life Assessment Drug: Selinexor	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04756401
NCT05541003	Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome	Drug: NBT-NM108	Rutgers, The State University of New Jersey	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05541003
NCT05478707	Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes	Drug: Dulaglutide Drug: Placebo Behavioral: exercise training	University of Virginia	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05478707
NCT05309616	Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis	Drug: Taltz	Yale University Lilly Pharmaceutical Company	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05309616
NCT05588453	Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the	Biological: Natural Killer Cell Therapy Drug: Temozolomide	Kari Kendra Ohio State University Comprehensive Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05588453
NCT05468359	Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients	Drug: Atezolizumab Drug: Sorafenib Drug: Bevacizumab Drug: Cyclophosphamide	St. Jude Children's Research Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05468359
NCT05419479	Switch Maintenance in Pancreatic	Drug: ZIMBERELIMAB Drug: DOMVANALIMAB Drug: APX005M Drug: FOLFIRI	James Cleary, MD, PhD Arcus Biosciences, Inc. Lustgarten Foundation Dana-Farber Cancer Institute	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05419479
NCT05114837	Ph I/II Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R/R CD19+ B-ALL	Drug: allogeneic CAR19 regulatory T cells (CAR19-tTreg) Drug: Fludarabine Drug: Cyclophosphamide	Masonic Cancer Center, University of Minnesota	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05114837
NCT05092451	Phase I/II Study of CAR.70-Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignancies	Drug: Cyclophosphamide Drug: CAR.70/IL15-transduced CB-NK cells Drug: Fludarabine phosphate	M.D. Anderson Cancer Center	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05092451
NCT02522611	Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain	Drug: Resiniferatoxin	National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT02522611
NCT05592626	A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid	Drug: STAR0602	Marengo Therapeutics, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05592626
NCT05566223	Phase 1/2 Study of CISH Inactivated TILs in the Treatment of NSCLC	Drug: Fludarabine Drug: Cyclophosphamide Biological: CISH Inactivated TIL Drug: Aldesleukin Drug: Pembrolizumab	Intima Bioscience, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05566223
NCT05548452	Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease	Drug: Intestinal Microbiota Transplant (IMT) Capsules Drug: Placebo Capsules	Virginia Commonwealth University National Institute on Alcohol Abuse and Alcoholism (NIAAA)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05548452
NCT05535244	A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma	Drug: Cevostamab Drug: Tocilizumab	Hoffmann-La Roche	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05535244
NCT05322590	BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma	Drug: BXQ-350 Other: Placebo	Bexion Pharmaceuticals, Inc. ICON plc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05322590
NCT05572463	A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic	Combination Product: Sintilimab + IBI110	Innovent Biologics (Suzhou) Co. Ltd. Innovent Biologics (USA), Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05572463
NCT05579366	PRO1184 for Advanced Solid Tumors	Drug: PRO1184	ProfoundBio US Co.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05579366
NCT05277168	A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS	Drug: SHR-A1904	Jiangsu HengRui Medicine Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05277168

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

NCT05607953	Pressure Enabled Intrapancratic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma	Drug: SD-101 Biological: pebrolizumab	TriSalus Life Sciences, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05607953
NCT05546723	LMY-920 for Treatment of Relapsed or Refractory Myeloma	Biological: Autologous CAR-T cell therapy expressing the BAFF-ligand.	Luminary Therapeutics The Cleveland Clinic Case Western Reserve University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05546723
NCT05526924	Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer	Radiation: Chemoradiation Drug: Pamiparib Drug: Hydroxyurea Drug: Fluorouracil (5FU) Drug: Tislelizumab	University of Chicago	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05526924
NCT05504837	A Study Assessing KB407 for the Treatment of Cystic Fibrosis	Biological: KB407 (Nebulization)	Krystal Biotech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05504837
NCT05500807	Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A	Drug: Emicizumab	Bleeding and Clotting Disorders Institute Peoria, Illinois Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05500807
NCT05464329	Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Autologous Stem Cell Transplant-Eligible Patients With Relapsed/Refractory Aggressive B Cell	Drug: Mosunetuzumab Drug: DHAX Drug: ICE	Washington University School of Medicine Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05464329
NCT05432635	Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma	Biological: Anti-CD19-CAR CMV-specific T-lymphocytes Procedure: Autologous Hematopoietic Stem Cell Transplantation Biological: Multi-peptide CMV-Modified Vaccinia Ankara Vaccine Procedure: Myeloablative Conditioning	City of Hope Medical Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05432635
NCT05400603	Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma	Combination Product: Ex Vivo Expanded Allogeneic 數灌 T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and	Emory University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05400603
NCT05400330	Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease	Biological: LX1001	Lexeo Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05400330
NCT05364424	A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant Eligible Diffuse B-Cell	Drug: Glofitamab Drug: Obinutuzumab Drug: Tocilizumab Drug: Rituximab Drug: Ifosfamide Drug: Carboplatin Drug: Etoposide	Hoffmann-La Roche	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05364424
NCT05283109	ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM	Biological: Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine Drug: Hiltonol	Mustafa Khasraw, MBChB, MD, FRCP, FRACP National Cancer Institute (NCI) Duke	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05283109
NCT05262556	TQ (Thymoquinone) Formula With Nivolumab and Ipilimumab in Gastroenteropancreatic Neuroendocrine Carcinomas	Drug: TQ Formula (black seed oil capsules) Drug: Nivolumab 240 mg Drug: Ipilimumab (1mg/kg)	Amr Mohamed MD Novatek Pharmaceuticals Case Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05262556
NCT05254184	KRAS-Targeted Vaccine With Nivolumab and Ipilimumab for Patients With NSCLC	Drug: Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05254184
NCT05234307	PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer	Drug: Adenosine A2B Receptor Antagonist PBF-1129 Procedure: Biospecimen Collection Biological: Nivolumab	Dwight Owen National Cancer Institute (NCI) Ohio State University Comprehensive Cancer	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05234307
NCT05228249	Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma	Procedure: Autologous Hematopoietic Stem Cell Transplantation Drug: Carmustine Drug: Cytarabine Drug: Etoposide Biological: Loncastuximab Tesirine Drug: Melphalan	Fred Hutchinson Cancer Center ADC Therapeutics	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05228249
NCT04881240	Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia	Biological: CD19-CAR(Mem) T-cells Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Device: CliniMACS Procedure: Leukapheresis	St. Jude Children's Research Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04881240
NCT04579523	²¹¹ At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Biological: Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10 Drug: Cyclophosphamide Drug: Fludarabine Phosphate Radiation: Total-Body Irradiation	Fred Hutchinson Cancer Center National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04579523

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

NCT03988283	Neopeptide-based Personalized DNA Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors	Biological: Personalized neoantigen DNA vaccine Device: TDS-IM System Procedure: Peripheral blood	Washington University School of Medicine Children's	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03988283
NCT05607095	A Study of LN-144 in People With Metastatic Uveal Melanoma	Biological: LN-144	Memorial Sloan Kettering Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05607095
NCT05585034	Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb 808 in Combination With Pembrolizumab in Advanced	Biological: XmAb 808 Biological: Keytruda (pembrolizumab)	Xencor, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05585034
NCT05354544	Evaluating Autologous Stromal Vascular Fraction in Subjects With	Biological: Autologous adipose derived SVF	Shane A. Shapiro Mayo Clinic	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05354544
NCT05244473	A Safety Study of Brentuximab Vedotin in Participants With HIV	Drug: brentuximab vedotin Drug: Placebo Drug: ART	Seagen Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05244473
NCT05581004	A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors	Drug: RO7502175 Drug: Atezolizumab	Genentech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05581004
NCT05476770	Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies	Drug: Tagraxofusp Drug: Fludarabine Drug: Cytarabine Drug: Dexamethasone Drug: Vincristine Drug: Azacitidine Drug: Methotrexate Drug: Cytarabine	Therapeutic Advances in Childhood Leukemia Consortium	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05476770
NCT05539729	Vancomycin Study in Multiple Sclerosis (MS)	Drug: Vancomycin Drug: Placebo	Icahn School of Medicine at Mount Sinai Doris Duke Charitable Foundation	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05539729
NCT05473910	A Study of TSC-100 and TSC-101 in AML, ALL and MDS Patients Undergoing Haploidentical Donor	Drug: SOC + TSC-100 Drug: SOC + TSC-101 Other: Control	TScan Therapeutics, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05473910
NCT05408871	Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial	Drug: adnectin 18F-BMS-986192 Head and Neck Cancer Drug: adnectin 18F-BMS-986192 Brain Metastases	Yale University National Cancer Institute (NCI)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05408871

○ 영국 5건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05567796	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo cagrilintide Drug: Placebo semaglutide	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05567796
NCT05529316	A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Drug: Botensilimab	Agenus Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05529316
NCT05572463	A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic	Combination Product: Sintilimab + IB1110	Innovent Biologics (Suzhou) Co. Ltd. Innovent Biologics (USA), Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05572463
NCT05552157	A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Drug: Gantenerumab Drug: Matching Placebo (Gantenerumab)	Washington University School of Medicine Hoffmann-La Roche Alzheimer's Association National Institute on Aging (NIA) Genentech, Inc.	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05552157
NCT05457283	A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	Drug: Finerenone (Kerendia, BAY94-8862)	Bayer	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05457283

○ 프랑스 9건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05578872	A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (ANV419-101).	Drug: ANV419 Drug: Pembrolizumab Drug: Ipilimumab	Anaveon AG	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05578872

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

NCT05545384	Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial	Drug: Immediate Azathioprine (1st attack) Drug: Immediate Rituximab (1st attack) Drug: Standard of care	Assistance Publique - Hôpitaux de Paris Institut National de la Santé Et de la Recherche Médicale, France	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05545384
NCT05552157	A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Drug: Gantenerumab Drug: Matching Placebo (Gantenerumab)	Washington University School of Medicine Hoffmann-La Roche Alzheimer's Association National Institute on Aging (NIA) Genentech,	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05552157
NCT04935684	Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation	Drug: Faecal Microbiota Transplantation	University Hospital, Clermont-Ferrand Ministry of Health, France French Society of Hematology	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04935684
NCT05529316	A Study of Botensilimab (AGEN1181) for the Treatment of Advanced	Drug: Botensilimab	Agenus Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05529316
NCT05559359	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis	Drug: Lebrikizumab Drug: Placebo Drug: Topical corticosteroid	Eli Lilly and Company Dermira, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05559359
NCT05287113	Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS≥1) Recurrent/Metastatic Squamous Cell	Drug: Retifanlimab Drug: INCAGN02385 Drug: INCAGN02390 Drug: Placebo	Incyte Biosciences International Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05287113
NCT05572463	A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic	Combination Product: Sintilimab + IBI110	Innovent Biologics (Suzhou) Co. Ltd. Innovent Biologics (USA), Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05572463
NCT05457283	A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and	Drug: Finerenone (Kerendia, BAY94-8862)	Bayer	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05457283

○ 독일 9건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05567796	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo cagrilintide Drug: Placebo semaglutide	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05567796
NCT05529316	A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma	Drug: Botensilimab	Agenus Inc.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05529316
NCT05559359	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis	Drug: Lebrikizumab Drug: Placebo Drug: Topical corticosteroid	Eli Lilly and Company Dermira, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05559359
NCT05287113	Study of Retifanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS≥1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck	Drug: Retifanlimab Drug: INCAGN02385 Drug: INCAGN02390 Drug: Placebo	Incyte Biosciences International Incyte Corporation	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05287113
NCT05572463	A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma	Combination Product: Sintilimab + IBI110	Innovent Biologics (Suzhou) Co. Ltd. Innovent Biologics (USA), Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05572463
NCT05552157	A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation	Drug: Gantenerumab Drug: Matching Placebo (Gantenerumab)	Washington University School of Medicine Hoffmann-La Roche Alzheimer's Association National Institute on Aging (NIA) Genentech,	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05552157
NCT05583227	Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis	Biological: Tezepelumab Other: Placebo	AstraZeneca Amgen	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05583227

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

NCT05457283	A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria	Drug: Finerenone (Kerendia, BAY94-8862)	Bayer	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05457283
NCT05570409	Immunosuppressive Treatment in Chronic Virus-Negative Inflammatory Cardiomyopathy	Drug: Mycophenolate Mofetil Drug: Prednisolone Drug: Mycophenolate Mofetil Placebo Drug: Prednisolone Placebo	LMU Klinikum Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK) Technical University of Munich Charite University, Berlin, Germany University Hospital, Essen University Hospital Erlangen University Hospital Tuebingen	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05570409

○ 중국 15건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05403138	Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders	Drug: Daratumumab Drug: Placebo	Tianjin Medical University General Hospital	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05403138
NCT05606263	Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer	Drug: Caldonirimab and Nimotuzumab	Health Science Center of Xi'an Jiaotong University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05606263
NCT05601505	Circulating Tumor DNA-guided Neoadjuvant Treatment Strategy for Locally Advanced Rectal Cancer	Other: circulating tumor DNA	Peking Union Medical College Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05601505
NCT05577923	Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)	Drug: Trastuzumab Drug: pyrotinib Drug: Dapiciclib Drug: fulvestrant	Fudan University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05577923
NCT05577091	Tris-CAR-T Cell Therapy for Recurrent Glioblastoma	Genetic: Inverse correlated dual-target, truncated IL7Ra modified CAR - expressing autologous T-lymphocytes.	Beijing Tiantan Hospital Beijing Neurosurgical Institute Tasly Pharmaceutical Group Co.,	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05577091
NCT05555888	The Combination of Immunotherapy and Neoadjuvant Short-course Radiotherapy in Early Rectal Cancer (TORCH-E)	Drug: PD-1 antibody Drug: Capecitabine Drug: Oxaliplatin Radiation: Short-course radiotherapy	Fudan University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05555888
NCT05540275	Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma	Drug: Sintilimab plus Bevacizumab	Henan Provincial People's Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05540275
NCT05524168	SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma	Radiation: SBRT Drug: Camrelizumab Drug: Gemcitabine Drug: Cisplatin	Sun Yat-sen University Shenzhen People's Hospital First People's Hospital of Foshan Jiangxi Provincial Cancer Hospital The First Affiliated Hospital of Xiamen University Chongqing University Cancer Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05524168
NCT05420584	Neoadjuvant Arterial Embolization Chemotherapy Combined PD-1 Inhibitor for Locally Advanced Rectal Cancer	Procedure: Arterial chemoembolization Drug: Tislelizumab Injection Drug: XELOX Diagnostic Test: Pelvic MRI Procedure: Laparoscopic radical resection of rectal cancer	The Fourth Affiliated Hospital of Zhejiang University School of Medicine Second Affiliated Hospital, School of Medicine, Zhejiang University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05420584

해외 바이오의약품 임상 현황 ('22년 11월 1주)

한국바이오의약품협회, 2022.11.08.

NCT05244798	Sintilimab Plus NCT or NCRT Versus NCRT for ESCC	Drug: Sintilimab Radiation: radiotherapy Drug: Chemotherapy	Sichuan Cancer Hospital and Research Institute Peking University Cancer Hospital & Institute Tianjin Medical University Cancer Institute and Hospital Hebei Medical University Fourth Hospital Anhui Provincial Hospital The First Affiliated Hospital with Nanjing Medical University Anyang	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05244798
NCT05567588	Pembrolizumab Plus Radiotherapy for Advanced Renal Cancer	Combination Product: Drug: Pembrolizumab	Nanfang Hospital of Southern Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05567588
NCT05585580	Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy	Drug: Serplulimab Drug: Lenvatinib Drug: Paclitaxel	Qilu Hospital of Shandong University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05585580
NCT05586061	First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer	Drug: Disitamab vedotin Drug: Tislelizumab Drug: S1	Qilu Hospital of Shandong University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05586061
NCT05583227	Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis	Biological: Tezepelumab Other: Placebo	AstraZeneca Amgen	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05583227
NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Drug: Alectinib Drug: Entrectinib Drug: Pralsetinib Drug: Durvalumab	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05170204

○ 일본 3건					
NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05567796	A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight	Drug: Cagrilintide Drug: Semaglutide Drug: Placebo cagrilintide Drug: Placebo semaglutide	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05567796
NCT05559359	A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis	Drug: Lebrikizumab Drug: Placebo Drug: Topical corticosteroid	Eli Lilly and Company Dermira, Inc.	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05559359
NCT05170204	A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)	Drug: Alectinib Drug: Entrectinib Drug: Pralsetinib Drug: Durvalumab	Hoffmann-La Roche	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05170204